Company: ABUS
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001447028-25-000115
Chunk: 19

Company: Arbutus Biopharma Corp
Filing Date: 2025-08-06
Form: 10-Q
Item: Part I, Item 1
Chunk 19
---
2024189,963,492 $1,410,025 $82,048 $(1,346,572)$(48,135)$97,366 Stock-based compensation expense— — 3,564 — — 3,564 Issuance of common shares pursuant to exercise of options892,857 4,616 (1,963)— — 2,653 Issuance of common shares pursuant to ESPP44,541 173 (42)— — 131 Issuance of common shares upon vesting of RSUs580,584 1,518 (1,518)— — — Unrealized loss on available-for-sale securities— — — — (31)(31)Net loss— — — (24,526)— (24,526)Balance March 31, 2025191,481,474 $1,416,332 $82,089 $(1,371,098)$(48,166)$79,157 Stock-based compensation expense— — 864 — — 864 Issuance of common shares pursuant to exercise of options160,037 778 (325)— — 453 Unrealized loss on available-for-sale securities— — — — (21)(21)Net income— — — 2,523 — 2,523 Balance June 30, 2025191,641,511 $1,417,110 $82,628 $(1,368,575)$(48,187)$82,976 

See accompanying notes to the condensed consolidated financial statements.

3

ARBUTUS BIOPHARMA CORPORATION

Condensed Consolidated Statements of Stockholders’ Equity

(Unaudited)

(In thousands of U.S. Dollars, except share amounts)

Common Shares Number of SharesShare CapitalAdditional Paid-In CapitalDeficitAccumulated Other Comprehensive LossTotal Stockholders' EquityBalance December 31, 2023169,867,414 $1,349,821 $81,270 $(1,276,652)$(48,421)$106,018 Stock-based compensation expense— — 2,014 — — 2,014 Issuance of common shares pursuant to the Open Market Sale Agreement8,666,077 21,765 — — —